Figure 5.
Figure 5. The effect of pretreatment with a combination of anti-L-selectin, anti-PSGL-1, and anti-β2 integrin mAbs (anti-WBC) on PAR-1 agonist peptide-reduced RBC velocity (VRBC) of XRITC-labeled sickle RBCs injected into C57BL/6 (control) mice. Results described are VRBC. Average velocities of labeled sickle RBCs (VRBC) in control (n = 6) or combination antibody-treated (n = 12) mice before (-) and 2 minutes after (+) PAR-1 agonist peptide suffusion. The error bars indicate the standard error of the mean.

The effect of pretreatment with a combination of anti-L-selectin, anti-PSGL-1, and anti-β2integrin mAbs (anti-WBC) on PAR-1 agonist peptide-reduced RBC velocity (VRBC) of XRITC-labeled sickle RBCs injected into C57BL/6 (control) mice. Results described are VRBC. Average velocities of labeled sickle RBCs (VRBC) in control (n = 6) or combination antibody-treated (n = 12) mice before (-) and 2 minutes after (+) PAR-1 agonist peptide suffusion. The error bars indicate the standard error of the mean.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal